SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following impressive vehicle delivery numbers for December and Q4, surpassing expectations and fueling community excitement about its substantial year-over-year growth and nearing a million cumulative deliveries. The stock's undervaluation is a key talking point, with many anticipating future profitability bolstered by extended EV subsidies and the unique battery swap infrastructure, despite ongoing debates about market manipulation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with mixed community sentiment as the new year unfolds, fueled by widespread speculation regarding its immediate price action. Enthusiasts are vocal about their hopes for a significant rally, anticipating fresh buying interest as year-end tax adjustments conclude. The ongoing conversation reflects both strong community loyalty and debates surrounding its long-term trajectory as a prominent meme coin.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with massive volume and significant price action following news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. While many in the community are bullish on its low float, anticipating a short squeeze and further gains, strong concerns are rapidly emerging regarding a recently announced private placement at a lower price, sparking fears of significant dilution.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending with a notable price surge, leading to a highly divided community conversation. Many are expressing frustration, calling it a "scam" due to perceived manipulation and past volatility, while others remain optimistic, citing its real-world utility through Flexa partnerships and potential for future institutional adoption, especially with upcoming regulatory clarity.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending due to its "Infinite Money Glitch" protocol, which consistently distributes passive Solana rewards to holders, cultivating a highly dedicated and resilient community. Despite recent chart movements, a strong bullish sentiment persists, fueled by anticipation for upcoming LP rewards, the imminent launch of real-time audit technology, and its ambitious aim to integrate with major gaming economies.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant community discussion around strategic moves to enhance its utility and institutional presence, particularly with the launch of Europe's first ETP. The community also eagerly anticipates a substantial token burn as it approaches a key holder milestone, fueling mixed sentiment and speculation about a potential rally within the Solana ecosystem.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is actively trending due to its Q3 earnings, significant advancements in AI and humanoid robotics, and strong pre-order demand for its new X9 EREV hybrid. Community sentiment is divided, with many citing undervaluation and global expansion as key bullish drivers, while others point to frustrating price drops and perceived market manipulation in the Chinese EV sector. Attention remains on upcoming delivery figures and the company's path to sustained profitability amidst new EV incentives.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to significant community discussion surrounding recent share dilution for executive compensation, leading to frustration over persistent underperformance despite its substantial Bitcoin holdings. Investors are actively debating the company's valuation, with some seeing deep undervaluation due to unpriced energy infrastructure and an AI/HPC pivot, while others express concerns about management and potential further downside amidst heavy short interest.

Pump.fun

PUMP.FUN is actively trending amid ongoing legal challenges, including a major lawsuit with whistleblower revelations and a former developer's sentencing, fueling speculation across the community. Many are debating whether current price action represents a "bear trap" or indicates deeper issues, even as affiliated meme projects within the Solana ecosystem rally for continued growth.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is seeing significant discussion following an unexpected Q3 loss and a cautious Q4 delivery outlook, which has fueled mixed sentiment within the investor community. Despite these challenges, the launch of the company's new AI-powered smart glasses is generating buzz, while renewed government subsidies for electric vehicles are providing a sector-wide tailwind, influencing views on Li Auto's new i6 SUV and broader market position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>The company said that 72 out of the prespecified 80 deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.</li><li>That extended survival timeline may delay the anticipated year-end 2025 reporting, but could indicate positive treatment impact if unblinded data confirms it.</li><li>The REGAL trial’s final scrutiny depends on reaching the event threshold.</li></ul>SELLAS Life Sciences Group Inc.’s (SLS) shares were in the spotlight on Wednesday after Maxim took an optimistic position regarding the Phase 3 clinical trial of galinpepimut-S (GPS) for acute myeloid leukemia (AML).&nbsp;The study’s contract research organization has informed the company that 72 out of the prespecified 80 patient deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.<h2 class="st-heading-2">Implications Of Delayed Trigger</h2>Maxim analyst Jason McCarthy noted that&nbsp;because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS.&nbsp;That extended survival timeline may delay the anticipated year-end 2025 reporting but could indicate positive treatment impact if unblinded data confirms it, added the firm.&nbsp;<a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences’ stock</a> traded over 4% higher on Wednesday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:941/109;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_31_105329_png_6820d21893.webp" alt="SLS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Dec. 31, 2025 | Source: Stocktwits" width="941" height="109"><figcaption>SLS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Dec. 31, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Event-Driven Analysis</h2>The ongoing GPS trial is an overall survival study, and the final analysis is expected once 80 deaths have occurred.&nbsp;“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou on Monday. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event.”GPS is SELLAS’ main drug candidate, and it works by targeting the WT1 protein found in many different cancers. The company is currently evaluating the drug as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.SLS stock has gained over 234% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-says-eightco-is-emerging-as-core-human-authentication-layer-of-digital-economy/cL7BOaURECc">Dan Ives Says Eightco Is Emerging As Core Human Authentication Layer Of Digital Economy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is SLS Stock Drawing Significant Investor Attention Today?

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS. 

Equity

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS. 


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Here's Why...

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial related updates.read more...

<ul class="summary-bullets"><li>As of December 26, 72 deaths have occurred, the company said on Monday.</li><li>SELLAS had said in August that it expects the 80 events to occur by year-end.&nbsp;</li><li>GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) traded 17% higher on Monday after the company said that it is approaching the final analysis of its late-stage trial in Acute Myeloid Leukemia. &nbsp;The company is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding. GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.<h2 class="st-heading-2">Final Analysis Nears</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspx">said</a> on Monday. SELLAS had said in August that it expects the 80 events to occur by year-end.“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results.”<h2 class="st-heading-2">Interim Analysis</h2>In August, an Independent Data Monitoring Committee completed a pre-specified analysis of the trial and issued a positive recommendation to continue the trial without modification. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct, the company then said.The study completed enrollment in April 2024, with a total of 126 patients randomized.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user called the current price “absurd” and opined the stock is worth double digits. “Right this second! Not tomorrow, not next week, not a year from now but immediately right this very second…DOUBLE DIGITS!,” they wrote.<stembedurl>https://www.stocktwits.com/Mr_Anderson007/message/640327741</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled this year and risen by about 239% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharmaceuticals-to-meet-with-fda-in-2026-to-advance-experimental-lyme-disease-prevention-drug/cL75CPSRExm">Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

How Is The Market Feeling About SELLAS Life Sciences Group Inc?

<ul class="summary-bullets"><li>SELLAS released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.&nbsp;</li><li>The company is also expected to release the final event-driven analysis for its galinpepimut-S (GPS) drug by the end of 2025.&nbsp;</li><li>Some retail investors anticipate a buyout or partnership in the near future based on its oncology drug pipeline.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been on investors’ radar over the past few weeks after the company released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.Shares of SLS are up over 78% in just a month and continue to rise as investors discuss the potential of the drug, forthcoming developments, and possibilities of an acquisition. The stock is up nearly 3% in Wednesday’s premarket trade at the time of writing.<h2 class="st-heading-2">Trial Updates</h2>The trial for the SLS009 drug involved combining it with azacitidine (AZA) and venetoclax (VEN) in patients diagnosed with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).Patients in the study with limited prior treatment achieved a median overall survival of 8.9 months, outperforming the historical benchmark of approximately 2.5 months for this patient population. Results showed a 46% overall response rate across all participants and a 58% overall response rate in patients with one prior line of therapy.SELLAS said it plans to expand the study of SLS009 in combination with azacitidine and venetoclax among acute myeloid leukemia patients in the first quarter of 2026.Apart from these positive trial results, users are also anticipating more information about the company’s galinpepimut-S (GPS) drug. Earlier this year, SELLAS had said that it expects the final event-driven analysis for the drug to be completed and reported by the end of 2025.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around SLS stock has remained in the ‘bullish’ territory for over a week, and message volume stayed at ‘high’ levels. The volume of retail messages for the stock has jumped 680% in the past month.Apart from the drug discussions, users are also actively discussing the possibility of an acquisition.One user pointed to the potential for a buyout or partnership, citing recent examples such as Cidara Therapeutics, which was bought by Merck for $9.2 billion.<stembedurl>https://stocktwits.com/DSCallez/message/640053184</stembedurl>Another bullish user echoed the sentiment, saying they were looking past trial success and focusing instead on who the buyer could be.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/640055860</stembedurl>A third user said that even if the company did not provide updates on the GPS drug by the end of the year, it was still performing better than anyone expected, and a longer wait would mean a higher buyout price.<stembedurl>https://stocktwits.com/BobWayne/message/640054317</stembedurl><a href="https://stocktwits.com/symbol/SLS">Shares of SLS</a> are up over 197% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About?

SLS Stock- Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 


SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading activity on Friday. Stock traders acquired 21,865 call options on the stock. This is...

<ul class="summary-bullets"><li>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment.</li><li>The main goal of the trial is to see whether the treatment helps patients live longer overall.</li><li>Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been drawing continued attention as investors are optimistic about the company’s potential following its positive results in acute myeloid leukemia (AML) treatment.&nbsp;The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 in patients with relapsed or refractory AML with myelodysplastic-related changes (AML-MR) and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences’ stock</a> inched 0.9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;A Stocktwits user said if GPS actually works, it will completely change the game, referring to the REGAL trial.<stembedurl>https://stocktwits.com/newTrader9999/message/639398804</stembedurl>Another user said the biggest clear advantage is that combining GPS with SLS009 could lengthen the life cycle of the standard of care to AML patients by many months or even years.<stembedurl>https://stocktwits.com/stockforce123/message/639395388</stembedurl><h2 class="st-heading-2">What Is Phase 3 REGAL Trial</h2>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment (CR2 patients). The main goal of the trial is to see whether the treatment helps patients live longer overall.The final review will begin after 80 events, meaning patient deaths, have taken place, which will help clarify how effective GPS may be for AML patients. At the moment, that number had not yet been met.Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%SLS stock has gained over 111% in 2025 and over 150% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-azi-stock-surge-today/cLeJ029REp3">Why Did AZI Stock Surge Over 12% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Senior scientist Zhou Han sets up a quantitative PCR (polymerase chain reaction).

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Still Bullish 

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

<ul class="summary-bullets"><li>SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.&nbsp;</li><li>Across the treated group, the overall response rate (ORR) reached 46%.</li><li>For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock came into the spotlight on Monday morning after encouraging results from its Phase 2 clinical trial for its investigational drug SLS009.&nbsp;The trial involved combining SLS009 with azacitidine (AZA) and venetoclax (VEN) in patients with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS’ stock</a> traded over 8% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img style="aspect-ratio:936/108;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_08_050240_png_2fc0723d0f.webp" alt="SLS’s Sentiment Meter and Message Volume as of 05:00 p.m. ET on Dec. 8, 2025 | Source: Stocktwits" width="936" height="108"><figcaption>SLS’s Sentiment Meter and Message Volume as of 05:00 a.m. ET on Dec. 8, 2025 | Source: Stocktwits</figcaption></figure>A Bullish Stocktwits user said there are many situations where Galinpepimut-S (GPS)and SLS009 can be used alongside venetoclax and azacitidine, creating a powerful multi-drug approach to wipe out AML.<stembedurl>https://stocktwits.com/Juhanialainen/message/638454494</stembedurl>GPS, SELLAS’ lead product candidate, is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein.Another user said they always prefer late-stage biotechs to have at least one more solid product or indication in development.<stembedurl>https://stocktwits.com/Sawnchey/message/638460062</stembedurl><h2 class="st-heading-2">Encouraging Response Rates</h2>In the study, 35 evaluable individuals, most with high-risk disease marked by adverse-risk genetics, received SLS009 intravenously at 30 mg twice weekly, alongside AZA/VEN.Across the treated group, the overall response rate (ORR), including complete remission (CR), complete remission with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS), reached 46%.Patients who had received minimal prior therapy experienced a median overall survival (mOS) of 8.9 months, far exceeding historical survival expectations of roughly 2.5 months in this patient subgroup. For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.SLS stock has gained over 67% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-ibm-may-want-confluent-3-charts-reveal-ai-play-s-promise/cLIYjkHREll">Why IBM May Want Confluent So Badly: 3 Charts Reveal AI Play's Promise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Traders are sharing enthusiastic New Year greetings and projecting significant growth and positive outcomes for the stock throughout 2026, often expressing confidence against detractors.

Current Price	$3.77
Prev Close	$3.31
Open	$3.46
Dividend Yield	0.00%
50-Day Moving Average	$1.94
Beta	0.94
Avg. Volume	3.45M
PE Ratio	-13.14

52-Week High	$3.99
52-Week Low	$0.8505
Market Capitalization	$471.48M
EPS (Annual)	-$0.5046
Price to Book	10.33
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc